Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 9/20 | 0.49 |
| ▸ | BIRC2 | Q13490 | 9/20 | 0.49 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.49 |
| ▸ | ACE | P12821 | 7/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17024560 | 1.00 | XIAP (0.49) | XIAPBIRC2BIRC3ACEABCB11 | |
| SCHEMBL18673908 | 1.00 | XIAP (0.49) | XIAPBIRC2BIRC3ACEABCB11 | |
| SCHEMBL17031947 | 0.91 | XIAP (0.48) | XIAPBIRC2BIRC3ACEABCB11 | |
| SCHEMBL18635864 | 0.89 | XIAP (0.43) | XIAPBIRC2BIRC3 | |
| SCHEMBL15639891 | 0.87 | XIAP (0.45) | XIAPBIRC2BIRC3ACEABCB11 | |
| SCHEMBL17024634 | 0.87 | XIAP (0.54) | XIAPBIRC2BIRC3 | |
| SCHEMBL17024635 | 0.87 | XIAP (0.54) | XIAPBIRC2BIRC3 | |
| SCHEMBL17024660 | 0.87 | XIAP (0.46) | XIAPBIRC2BIRC3ACEHDAC1 | |
| SCHEMBL17024658 | 0.87 | XIAP (0.46) | XIAPBIRC2BIRC3ACEHDAC1 | |
| SCHEMBL18635823 | 0.87 | CFTR (0.42) | XIAPBIRC2BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603889-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603889-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2903998-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2903998-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20150238558-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150238558-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238558-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | XIAP 1/4885BIRC2 4/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.